Who is who in differentiation of Trm-like TIL
Immunity · 2025
DOI: 10.1016/j.immuni.2025.06.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2025. Verfasst von Artun Bülbül und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, German Cancer Research Center, Heidelberg, Germany. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immunologic Memory, Lymphocytes, Tumor-Infiltrating. Die Arbeit nennt 10 Literaturangaben. Gefördert von: German Research Foundation, German Cancer Aid, European Research Council.
Abstract (Originalsprache)
Tumor-infiltrating CD8+ T cells with a tissue-resident memory phenotype have been described in both mice and humans. In this issue of Immunity, Green et al. provide a detailed analysis of the transcriptional and epigenetic regulation of these cells in relation to bona fide tissue-resident and exhausted T cells found in acutely resolving and chronic viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Immunology, German Cancer Research Center, Heidelberg, Germany.
- Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany.
- Division of Immunology, German Cancer Research Center, Heidelberg, Germany; Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München (TUM), Munich, Germany. Electronic address: veit.buc…
Förderung
- German Research Foundation
- German Cancer Aid
- European Research Council
Zitieren
APA
Bülbül, A., Hönninger, J., & Buchholz, V. R. (2025). Who is who in differentiation of Trm-like TIL. Immunity. https://doi.org/10.1016/j.immuni.2025.06.013
Vancouver
Bülbül A, Hönninger J, Buchholz VR. Who is who in differentiation of Trm-like TIL. Immunity. 2025. doi:10.1016/j.immuni.2025.06.013
BibTeX
@article{Blbl2025,
author = {Bülbül, Artun and Hönninger, Julian and Buchholz, Veit R},
title = {Who is who in differentiation of Trm-like TIL},
journal = {Immunity},
year = {2025},
doi = {10.1016/j.immuni.2025.06.013}
}
EUVIMED